Subject:
- Active Substance: Olopatadin / mometason
- Name: Ryaltris®
- Therapeutic area: Allergic rhinitis
- Pharmaceutical company: Berlin-Chemie AG
Time table:
- Start: 01.12.2022
- Final decision by G-BA: 01.06.2023
Final decision:
- No additional benefit proved